No Data
No Data
Oppenheimer Maintains Outperform on Sutro Biopharma, Maintains $10 Price Target
Oppenheimer analyst Jay Olson maintains Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $10 price target.
Oppenheimer Sticks to Their Buy Rating for Sutro Biopharma (STRO)
Sutro Biopharma Price Target Maintained With a $8.00/Share by Wedbush
Sutro Biopharma Price Target Maintained With a $8.00/Share by Wedbush
Express News | HC Wainwright & Co. Reiterates Buy on Sutro Biopharma, Maintains $12 Price Target
Sutro Biopharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 169.66% HC Wainwright & Co. → $12 Reiterates Buy → Buy 05/08/2024 169.66% B of A Securities → $
Buy Rating on Sutro Biopharma: Promising Trials and Market Expansion Potential for Luvelta